Rapt Scraps Zelnecirnon, But Not Giving Up On CCR4

The company said it does not see a development path for zelnecirnon based on feedback from the US FDA. It halted two Phase II trials in asthma and atopic dermatitis earlier this year.

Key Takeaways

Rapt Therapeutics is terminating development of its lead drug, the CCR4 antagonist zelneciron, which was in development for atopic dermatitis and asthma.
Zelneciron was put on a clinical trial hold earlier this year after a single case of liver injury emerged in a Phase IIb trial.
The company cut 40% of its workforce in July and had $114.8m in cash at the end of the second quarter.

Rapt Therapeutics does not see a development path for its lead drug candidate zelneciron (RPT193), so it is terminating development – though not completely giving up on the C-C motif...

The news sent the company’s already beleaguered stock down 44%to open the day at $1.50.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

21 May 2025

• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.